Zacks: Analysts Anticipate Eagle Pharmaceuticals Inc (EGRX) Will Post Earnings of $0.96 Per Share

Wall Street brokerages expect Eagle Pharmaceuticals Inc (NASDAQ:EGRX) to announce earnings of $0.96 per share for the current quarter, according to Zacks. Two analysts have made estimates for Eagle Pharmaceuticals’ earnings. The lowest EPS estimate is $0.76 and the highest is $1.16. Eagle Pharmaceuticals reported earnings of $0.49 per share during the same quarter last year, which suggests a positive year-over-year growth rate of 95.9%. The firm is expected to report its next earnings report on Wednesday, August 8th.

On average, analysts expect that Eagle Pharmaceuticals will report full-year earnings of $3.52 per share for the current financial year, with EPS estimates ranging from $3.24 to $3.93. For the next financial year, analysts expect that the company will post earnings of $4.51 per share, with EPS estimates ranging from $3.98 to $4.96. Zacks’ EPS calculations are an average based on a survey of sell-side research firms that cover Eagle Pharmaceuticals.

Eagle Pharmaceuticals (NASDAQ:EGRX) last issued its earnings results on Thursday, May 10th. The specialty pharmaceutical company reported $0.53 earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of $0.68 by ($0.15). Eagle Pharmaceuticals had a return on equity of 21.89% and a net margin of 15.32%. The firm had revenue of $46.60 million during the quarter, compared to analyst estimates of $48.88 million. During the same period in the previous year, the company earned $1.42 EPS. Eagle Pharmaceuticals’s revenue for the quarter was down 39.3% on a year-over-year basis.

A number of equities analysts have issued reports on EGRX shares. Zacks Investment Research cut Eagle Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Thursday, March 1st. Mizuho reaffirmed a “sell” rating and issued a $40.00 target price on shares of Eagle Pharmaceuticals in a report on Thursday, May 10th. Royal Bank of Canada set a $71.00 target price on Eagle Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, February 26th. BidaskClub raised Eagle Pharmaceuticals from a “buy” rating to a “strong-buy” rating in a report on Saturday, May 19th. Finally, ValuEngine cut Eagle Pharmaceuticals from a “hold” rating to a “sell” rating in a report on Wednesday, May 2nd. Three analysts have rated the stock with a hold rating, three have given a buy rating and one has assigned a strong buy rating to the company’s stock. Eagle Pharmaceuticals currently has an average rating of “Buy” and an average target price of $71.25.

Hedge funds have recently modified their holdings of the company. Smith Asset Management Group LP acquired a new stake in shares of Eagle Pharmaceuticals in the fourth quarter valued at about $187,000. Matarin Capital Management LLC bought a new stake in shares of Eagle Pharmaceuticals during the 1st quarter valued at about $208,000. Jane Street Group LLC bought a new stake in shares of Eagle Pharmaceuticals during the 1st quarter valued at about $212,000. MetLife Investment Advisors LLC bought a new stake in shares of Eagle Pharmaceuticals during the 4th quarter valued at about $218,000. Finally, Gargoyle Investment Advisor L.L.C. bought a new stake in shares of Eagle Pharmaceuticals during the 1st quarter valued at about $221,000.

Eagle Pharmaceuticals traded up $0.42, reaching $75.73, on Wednesday, according to MarketBeat.com. The stock had a trading volume of 3,482 shares, compared to its average volume of 233,330. Eagle Pharmaceuticals has a fifty-two week low of $45.05 and a fifty-two week high of $84.20. The company has a quick ratio of 5.66, a current ratio of 5.87 and a debt-to-equity ratio of 0.23. The stock has a market cap of $1.08 billion, a PE ratio of 22.52 and a beta of 1.47.

About Eagle Pharmaceuticals

Eagle Pharmaceuticals, Inc, a specialty pharmaceutical company, focuses on developing and commercializing injectable products primarily in the critical care and oncology areas in the United States. The company offers argatroban for heparin-induced thrombocytopenia; Ryanodex for malignant hyperthermia; non-alcohol docetaxel injection, a chemotherapeutic agent for breast, non-small cell lung, prostate, head, and neck cancers/gastric adenocarcinoma; and Bendeka for chronic lymphocytic leukemia (CLL) and indolent B-cell non-Hodgkin's lymphoma (NHL).

Get a free copy of the Zacks research report on Eagle Pharmaceuticals (EGRX)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Eagle Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Eagle Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.


Leave a Reply